Company: BNBX
Filing Date: 2025-01-17
Form Type: 424B3
Source: 0001104659-25-004510
Chunk: 18

Company: BNB PLUS CORP.
Filing Date: 2025-01-17
Form: 424B3
Chunk 18
---
 of proceeds | We will not                                                                                                                        
 receive any proceeds from the Common Stock offered by the Selling Stockholders under this prospectus. However, we will receive the 
 proceeds of any cash exercise of the Private Placement Warrants. We intend to use the net proceeds from any cash exercise of the   
 Private Placement Warrants for further development of our Therapeutic DNA Production Services, as well as for working capital and  
 general corporate purposes. See “Use of Proceeds.”                                                                                 |

| Market           
 for Common Stock | Our                                                                                        
 Common Stock is listed on The Nasdaq Capital Market under the symbol “APDN.”               
 On January 15, 2025, the last reported sale price of our Common Stock was $0.20 per share. |

| Risk    
 Factors | See “Risk                                                                                                      
 Factors” beginning on page 8 and the other information included in this prospectus for a discussion of factors 
 you should carefully consider before investing in our securities.                                              |

The number of shares of our Common Stock to
be outstanding after this offering is based on the 55,188,523 shares of our Common Stock outstanding as of January 8, 2025, and excludes
the following:

| · | 107,243 shares                                                                            
 of Common Stock issuable upon exercise of options outstanding as of January 8, 2025, with 
 a weighted average exercise price of $173.09 per share;                                   |

<div align='center'>7</div>

| · | 91,791,191                                                                                     
 shares of Common Stock issuable upon exercise of warrants outstanding as of January 8, 2025,   
 with a weighted average exercise price of $0.44 per share (which includes an aggregate of      
 88,247,534 May 2024 Series A Warrants (reflecting the Price Reset Mechanism being              
 triggered by the Offering) and May 2024 Series B Warrants, of which 2,257,052 have             
 an alternative cashless exercise mechanism representing the right to receive 3 shares of       
 Common Stock for each warrant, which, if exercised, would result in 6,771,156 shares of Common 
 Stock being issued);                                                                           |

| · | 41,640,625                                                                                                                        
 shares of Common Stock issuable upon exercise of the Private Placement Warrants, whose exercise is subject to Warrant Stockholder 
 Approval, of which 20,312,500 have an alternative cashless exercise mechanism representing the right to receive 1 share of Common